75294 NM_178919 NM_001163491 NM_008457 NM_001038010 NM_009699 NM_010642 NM_010643 NM_013554 NM_001039677 NM_001301853 NM_019939 NM_021443 NM_021564 NM_023816 NM_023873 NM_001008546 NM_001159553 NM_001177464 NM_001310682 NM_007809 NM_007941 NM_009650 NM_010145 NM_010582 NM_011908 NM_013777 NM_019779 NM_Gene Symbol 3M Acvr1 Klk1b22 Zfp385a Klk1b27 Tmcc3 Itpkb Fam129a Kcng4 Mex3c Tbccd1 Rbl2 Xpnpep3 Clpb Idh1 Pgrmc1 Cmpk1 Tnrc6b Nucks1 Lmf2 Sema4a Klk1b8 Kat2a Aqp2 Klk1b21 Klk1b24 Hoxd10 Slc30a2 Stk11 Mpp6 Ccl8 Fetub Ankrd36 Cep70 Tardbp H13 Zfp516 Prkcd Cyp17a1 Stx2 Akap3 Ephx1 Itih2 Ubl3 Akr1c12 Cyp11a1 8030462N17Rik 1.16 four.36 0.00 12.33 1.81 2.85 three.36 0.09 12.72 0.15 1.92 2.60 10.02 five.08 36.82 five.82 1.15 0.24 8.59 0.12 six.27 0.62 2.79 16.36 16.44 0.50 1.37 0.24 11.41 0.72 0.40 two.21 1.59 1.29 1.62 1.43 0.66 77.11 8.06 148.84 32.38 three.83 39.60 0.74 34.14 1.49 6M 0.26 1.63 0.01 5.92 1.39 1.23 0.92 0.77 7.02 0.15 1.02 1.48 eight.83 2.89 28.19 four.32 1.02 0.40 eight.09 0.49 two.70 1.18 1.82 eight.22 9.93 0.57 4.14 1.54 37.46 2.28 1.59 0.82 0.75 0.69 1.37 1.26 1.20 65.52 5.07 274.92 30.42 2.76 26.48 1.29 25.92 0.94 12M 0.01 0.33 1.59 1.98 0.51 0.62 0.75 1.28 4.52 0.16 0.62 1.13 7.53 two.34 16.46 2.46 0.70 0.50 5.64 1.49 0.01 two.49 0.76 3.01 three.53 1.45 5.35 2.87 39.21 2.32 2.61 0.47 0.58 0.44 0.90 0.86 1.36 40.81 four.08 318.80 17.68 1.97 23.20 1.67 16.40 0.52 18M 0.00 0.14 3.40 0.93 0.00 0.01 0.09 three.50 0.46 1.01 0.00 0.05 two.69 0.92 6.24 0.99 0.04 1.37 2.06 1.55 0.01 three.72 0.62 1.72 1.92 1.59 5.77 3.15 46.83 two.70 three.71 0.45 0.41 0.42 0.53 0.57 2.52 28.29 2.82 330.13 14.66 1.27 16.98 two.36 11.67 0.3M8Mp-Value 1 eight.98 10-58 4.52 10-4 four.12 10-6 three.96 10-56 4.62 10-7 1.70 10-77 7.93 10-6 six.89 10-5 1.13 10-7 3.88 10-7 9.08 10-5 eight.90 10-72 3.70 10-4 four.03 10-7 1.74 10-20 6.39 H2 Receptor Agonist Accession 10-117 2.51 10-10 3.43 10-5 1.52 10-3 five.96 10-17 9.23 10-11 1.12 10-3 3.70 10-10 four.60 10-6 6.06 10-48 five.51 10-5 two.19 10-87 1.90 10-20 four.51 10-11 four.32 10-4 1.63 10-12 1.31 10-4 1.87 10-4 2.37 10-5 five.98 10-12 7.70 10-7 1.22 10-3 1.12 10-15 two.63 10-4 1.21 10-8 two.59 10-7 eight.63 10-10 4.78 10-6 7.77 10-21 2.39 10-7 two.31 10-Expression Pattern Inc/Dec two CaMK II Inhibitor Formulation Decreased Decreased Elevated Decreased Decreased Decreased Decreased Improved Decreased Enhanced Decreased Decreased Decreased Decreased Decreased Decreased Decreased Increased Decreased Enhanced Decreased Improved Decreased Decreased Decreased Elevated Elevated Elevated Improved Increased Elevated Decreased Decreased Decreased Decreased Decreased Elevated Decreased Decreased Enhanced Decreased Decreased Decreased Elevated Decreased Decreased Kind eight 8 8 8 7 six 6 six five five 5 five five 5 five five five 5 5 4 four three 3 three 3 three 2 two two two 2 2 two 1 1 1 1 1 1 1 1 1 1 1 13M8M p-value: p-value calculated by DESeq2 for the 3M vs. 18M age groups. two Inc/Dec: increased or decreased expression pattern.three.six. Potential Cis-Regulatory Targets of Aging-Related lncRNAs Many functional lncRNAs are known to act inside a cis-regulatory manner. To investigate the possible cis-regulatory targets of your 34 aging-related lncRNAs described above (Figure 4), we analyzed nearby genomic regions utilizing Genomic Regions Enrichment of Annotations Tool (Wonderful) [24]. This technique identified 56 protein-coding genes that have been located in genomic regions close to the identified aging-related lncRNAs, and could as a result beCells 2021, 10,10 ofpotential cis-regulatory targets. Indeed, 5 of those neighboring genes have been identified to show alterations in the course of aging: The mRNA expression levels of four decreased (Agtpbp1, Suds3, 2410089E03Rik, and Te